Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient? : Targeting the cell death-survival equationRIXE, Olivier; FOJO, Tito.Clinical cancer research. 2007, Vol 13, Num 24, pp 7280-7287, issn 1078-0432, 8 p.Article

RENAL CELL CARCINOMARIXE, Olivier; RINI, Brian.Targeted oncology. 2010, Vol 5, Num 2, issn 1776-2596, 85 p.Serial Issue

Perspectives in drug development for metastatic renal cell cancerBASU, Bristi; EISEN, Tim.Targeted oncology. 2010, Vol 5, Num 2, pp 139-156, issn 1776-2596, 18 p.Article

Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiformeMANSOUR, Joshua; FIELDS, Braxton; MACOMSON, Samuel et al.Targeted oncology. 2014, Vol 9, Num 4, pp 395-398, issn 1776-2596, 4 p.Article

Sunitinib malateIZZEDINE, Hassane; BUHAESCU, Irina; RIXE, Olivier et al.Cancer chemotherapy and pharmacology. 2007, Vol 60, Num 3, pp 357-364, issn 0344-5704, 8 p.Article

Emerging molecular classification in renal cell carcinoma: implications for drug developmentHACKER, Kathryn E; RATHMELL, W. Kimryn.Targeted oncology. 2010, Vol 5, Num 2, pp 75-84, issn 1776-2596, 10 p.Article

Peripheral neuropathy in association with an ovarian dysgerminomaIVANAJ, Arben; PAUTIER, Patricia; RIXE, Olivier et al.Gynecologic oncology (Print). 2003, Vol 89, Num 1, pp 168-170, issn 0090-8258, 3 p.Article

Targeted therapy for locally advanced renal cell carcinomaJONASCH, Eric; TANNIR, Nizar M.Targeted oncology. 2010, Vol 5, Num 2, pp 113-118, issn 1776-2596, 6 p.Article

Validation of Analytic Methods for Biomarkers Used in Drug Development : Biomarker statistics in cancer researchCHAU, Cindy H; RIXE, Olivier; MCLEOD, Howard et al.Clinical cancer research (Print). 2008, Vol 14, Num 19, pp 5967-5976, issn 1078-0432, 10 p.Article

Targeted therapies for renal cell carcinoma: understanding their impact on survivalSUMANTA KUMAR PAL; FIGLIN, Robert A.Targeted oncology. 2010, Vol 5, Num 2, pp 131-138, issn 1776-2596, 8 p.Article

Angiogenesis inhibitor therapies : Focus on kidney toxicity and hypertensionIZZEDINE, Hassane; RIXE, Olivier; BILLEMONT, Bertrand et al.American journal of kidney diseases. 2007, Vol 50, Num 2, pp 203-218, issn 0272-6386, 16 p.Article

Visibilité nationale des tumorothèques et cadre d'interopérabilité. 2. Le projet de tumorothèque virtuelle nationale = National visibility of tumor banks and framework for interoperability. 2. The national virtual tumor bank projectBOUCHER, Pascal; BUYSE, Marc; AMALRIC, Francois et al.Bulletin du cancer. 2006, Vol 93, issn 0007-4551, S246-S248, NSArticle

Les anémies des cancéreux avant traitement = Anemia of cancer before any treatmentAUCLERC, Gérard; MERIC, Jean-Baptiste; POMMEYROL, Arlette et al.Bulletin du cancer. 2003, Vol 90, pp 128-132, issn 0007-4551, 5 p., NSArticle

Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective studyMOUAWAD, Roger; RIXE, Olivier; MERIC, Jean-Baptiste et al.Cytokines, cellular & molecular therapy. 2002, Vol 7, Num 4, pp 151-156, issn 1368-4736, 6 p.Article

Targeted therapies for non-clear renal cell carcinomaSINGER, Eric A; BRATSLAVSKY, Gennady; LINEHAN, W. Marston et al.Targeted oncology. 2010, Vol 5, Num 2, pp 119-129, issn 1776-2596, 11 p.Article

Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case reportSEAN XIANG WANG; BYRNES, Abigail; VERMA, Sadhna et al.Targeted oncology. 2010, Vol 5, Num 1, pp 59-63, issn 1776-2596, 5 p.Article

Prognostic and predictive biomarkers in renal cell carcinomaVICKERS, Michael M; HENG, Daniel Y. C.Targeted oncology. 2010, Vol 5, Num 2, pp 85-94, issn 1776-2596, 10 p.Article

L'inhibition du protéasome : une nouvelle approche thérapeutique en onco-hématologie = Proteasome inhibition : a new therapeutic approach in malignanciesSPANO, Jean-Philippe; BAY, Jacques-Olivier; BLAY, Jean-Yves et al.Bulletin du cancer. 2005, Vol 92, Num 11, pp 945-952, issn 0007-4551, 8 p.Article

Les anémies des cancéreux avant traitement = Anemia of cancer before any treatmentAUCLERC, Gérard; MERIC, Jean-Baptiste; POMMEYROL, Arlette et al.Bulletin du cancer. 2003, Vol 90, pp S128-S132, issn 0007-4551, NSArticle

Renal toxicity of targeted therapiesKELLY, Ronan J; BILLEMONT, Bertrand; RIXE, Olivier et al.Targeted oncology. 2009, Vol 4, Num 2, pp 121-133, issn 1776-2596, 13 p.Article

Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid TumorsRINI, Brian I; SCHILLER, Joan H; KIM, Sinil et al.Clinical cancer research (Print). 2011, Vol 17, Num 11, pp 3841-3849, issn 1078-0432, 9 p.Article

Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management : The renal insufficiency and anticancer medications (IRMA) studyLAUNAY-VACHER, Vincent; OUDARD, Stéphane; JANUS, Nicolas et al.Cancer. 2007, Vol 110, Num 6, pp 1376-1384, issn 0008-543X, 9 p.Article

Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study designKHAYAT, David; RIXE, Olivier; BRUNET, René et al.Cancer chemotherapy and pharmacology. 2004, Vol 54, Num 3, pp 193-205, issn 0344-5704, 13 p.Article

Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumoursVAN CUTSEM, Eric; KHAYAT, David; VERSLYPE, Chris et al.European journal of cancer (1990). 2013, Vol 49, Num 1, pp 17-24, issn 0959-8049, 8 p.Article

Place de l'imagerie par Tomographie par Émission de Positons pour les tumeurs stromales gastro-intestinales = The role of PET scan in gastrointestinal stromal tumorsALBERINI, Jean-Louis; AL NAKIB, Malik; WARTSKI, Myriam et al.Gastroentérologie clinique et biologique. 2007, Vol 31, Num 6-7, pp 585-593, issn 0399-8320, 9 p.Article